Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.
Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.